Journal article

Reversal of Transfusion Dependence by Tumor Necrosis Factor Inhibitor Treatment in a Patient With Concurrent Rheumatoid Arthritis and Primary Myelofibrosis

Anderson Ong, Hang Quach, Michelle Leech

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2011

Abstract

Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine with pleiotropic effects. Currently, TNF-α inhibitors are approved by the Food and Drug Administration for a number of diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, and ulcerative colitis. We report a patient with seropositive rheumatoid arthritis with concurrent primary myelofibrosis, who had transfusion-dependent anemia and moderate thrombocytopenia that reversed during treatment with adalimumab. Rheumatoid arthritis and myeloproliferative disorder or myelodysplastic disorder often coexist, and treatment with standard immunosuppressants becomes..

View full abstract

University of Melbourne Researchers